FARAPULSE PFA
MarketedPulsed field ablation system for atrial fibrillation, the first approved in Korea (September 2024); both 2D and 3D catheters have been reimbursed by national health insurance since 1 May 2026.
FROM PUBLIC EVENTS · 2026-11-18
Commercial · sales Has secured Korean approvals and insurance coverage for its atrial fibrillation devices in succession.
Roles often seen at this stageDevice R&D & support · Regulatory affairs · Sales & marketing
The Korean arm of Boston Scientific, supplying medical devices in Korea for cardiac rhythm, electrophysiology, interventional cardiology, structural heart, endoscopy, neuromodulation, peripheral intervention and urology.
Pulsed field ablation system for atrial fibrillation, the first approved in Korea (September 2024); both 2D and 3D catheters have been reimbursed by national health insurance since 1 May 2026.
The latest generation of the WATCHMAN left atrial appendage closure device, approved in Korea in 2025.
National health insurance reimbursement began in Korea for the FARAPULSE PFA platform.
The FARAWAVE NAV catheter and FARAVIEW software for 3D mapping received approval from Korea's MFDS.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.